after enrollment you will attend the first clinic visit where a study coordinator will confirm eligibility and explain the schedule.

you will receive an intravenous infusion of durvalumab at a dose of 1500 mg. the medicine is given through a vein over a period of time as directed by the medical team.

at the same visit you will be given either the study drug mk-1084 in the form of a film‑coated tablet or a matching placebo tablet. the exact amount of the tablet is defined by the study protocol.

each day you will take the assigned tablet by mouth with water, following the same time each day.

the tablet is designed to be swallowed whole and should not be crushed or chewed.

if you are assigned the placebo, the tablet will contain no active medication but will look identical to the study drug.

you will return to the clinic for additional durvalumab infusions according to the study schedule, typically every few weeks.

each infusion will again be 1500 mg given by intravenous route.

the clinic staff will monitor you during the infusion for any immediate reactions.

at each infusion visit you will have blood tests taken to check how your body is responding to the treatment.

imaging studies such as scans may be performed at predefined intervals to evaluate the status of the lung cancer.

you will complete quality‑of‑life questionnaires that ask about symptoms and daily functioning.

you are asked to inform the study team of any new symptoms, discomfort, or changes in health as soon as they occur.

common side effects may include fatigue, nausea, or reactions at the infusion site, but you will be instructed on how to recognize and report them.

you will continue taking the oral tablet daily and receiving the scheduled infusions until the study ends, the disease shows progression, or a serious adverse event requires stopping the medication.

the decision to stop treatment will be made by the investigators based on safety and disease status.